⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6912857 | 0.80 | — | — | |
| SCHEMBL6916240 | 0.80 | — | — | |
| SCHEMBL6915635 | 0.80 | — | — | |
| SCHEMBL6915942 | 0.80 | — | — | |
| SCHEMBL1085851 | 0.75 | — | — | |
| SCHEMBL503261 | 0.75 | — | — | |
| SCHEMBL1576713 | 0.75 | — | — | |
| SCHEMBL6907593 | 0.74 | TSHR (0.39) | — | |
| SCHEMBL10411794 | 0.73 | — | — | |
| SCHEMBL6281308 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116583502-A | Bicyclic-heterocyclic derivatives and their use as orexin-2 receptor agonists | 欧瑞夏治疗有限公司 | 2023-08-11 | — | — | CN | disclosed |
| US-20230161249-A1 | ACTINIC RAY-SENSITIVE OR RADIATION-SENSITIVE RESIN COMPOSITION, ACTINIC RAY-SENSITIVE OR RADIATION-SENSITIVE FILM, PATTERN FORMING METHOD, METHOD FOR MANUFACTURING ELECTRONIC DEVICE, AND COMPOUND | FUJIFILM CORPORATION (JP) | 2023-05-25 | — | — | US | disclosed |
| CN-106117193-B | New Hete rocyclic derivatives and its application in neurogenic disease treatment | 诺华股份有限公司 | 2019-09-13 | — | — | CN | disclosed |
| CN-106117193-A | New Hete rocyclic derivatives and the application in nervous system disease is treated thereof | 诺华股份有限公司 | 2016-11-16 | — | — | CN | disclosed |
| CN-103403001-B | Heterocyclic derivatives and their use in the treatment of neurological disorders | 诺瓦提斯公司 | 2016-08-17 | — | — | CN | disclosed |
| CN-103596569-A | BACE-2 inhibitors for the treatment of metabolic disorders | NOVARTIS AG | 2014-02-19 | — | — | CN | disclosed |
| CN-103403001-A | Novel heterocyclic derivatives and their use in the treatment of neurological disorders | NOVARTIS AG | 2013-11-20 | — | — | CN | disclosed |
| EP-1059927-B1 | CHEMICAL COMPOUNDS AND THEIR USE TO ELEVATE PYRUVATE DEHYDROGENASE ACTIVITY | ASTRAZENECA AB (SE) | 2008-07-30 | — | — | EP | disclosed |
| CN-1038413-C | Therapeutic amides | ZENECA LTD (GB) | 1998-05-20 | — | — | CN | disclosed |
| US-5684198-A | N-ARYL-2-HYDROXYPROPANAMIDES | IMPERIAL CHEMICAL INDUSTRIES, PLC (GB) | 1997-11-04 | — | — | US | disclosed |
| US-5567735-A | CELL POTASSIUM CHANNEL MODULATOR FOR TREATING ASTHMA | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1996-10-22 | — | — | US | disclosed |
| US-5565477-A | TREATMENT OF URINARY INCONTINENCE | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1996-10-15 | — | — | US | disclosed |
| US-5565465-A | TREATMENT OF URINARY INCONTINENCE | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1996-10-15 | — | — | US | disclosed |
| EP-0524781-B1 | Therapeutic amides | ZENECA LTD (GB) | 1996-03-27 | — | — | EP | disclosed |
| US-5474999-A | Useful in treatment of urinary incontinence | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1995-12-12 | — | — | US | disclosed |
| US-5382598-A | Therapeutic amides | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1995-01-17 | — | — | US | disclosed |
| US-5272163-A | Therapeutic amides | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-12-21 | — | — | US | disclosed |
| CN-1069727-A | The acid amides that is used for the treatment of | ICI PLC (GB) | 1993-03-10 | — | — | CN | disclosed |
| EP-0524781-A1 | Therapeutic amides | ZENECA LIMITED (GB) | 1993-01-27 | — | — | EP | disclosed |